Not Yet Recruiting PHASE2 INTERVENTIONAL 2-arm
NCT07340164
Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy (TROY)
A Phase 2, Open-label, Multicenter, Randomized Study of Trastuzumab Deruxtecan Versus Investigator's Choice Chemotherapy in Recurrent Ovarian Cancer That Progressed on Prior PARP Inhibitor Therapy: TROY (APGOT-OV14)
Sponsor: Boryung Pharmaceutical Co., Ltd
Conditions
Ovarian Cancer Ovarian Cancer (OvCa) Ovarian Cancer Metastatic Recurrent Ovarian Carcinoma, Recurrent
Interventions
Bevacizumab Platinum Based Chemotherapy Trastzumab Deruxtecan
Updated 1 time since 2026 Last updated: Jan 5, 2026 Started: Dec 30, 2025 Primary completion: Dec 30, 2026 Completion: Dec 31, 2030
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE2 clinical study on Ovarian Cancer and Ovarian Cancer (OvCa), this trial is actively recruiting participants. The trial is conducted by Boryung Pharmaceutical Co., Ltd and has accumulated 1 data snapshot since 2025. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Boryung Pharmaceutical Co., Ltd
- Daiichi Sankyo
- Yonsei University
Data source: Yonsei University
For direct contact, visit the study record on ClinicalTrials.gov .